Roivant Sciences (NASDAQ: ROIV) — Company Overview, News & Financial Data
Roivant Sciences applies technology to drug development, creating biotech companies to address significant medical challenges efficiently.
Roivant Sciences
Roivant Sciences is a commercial-stage biopharmaceutical company focused on building subsidiary biotech entities, known as Vants, to develop and commercialize targeted medicines and health technologies. Each Vant operates as an agile business dedicated to specific therapeutic areas, including immunology, dermatology, and pulmonary disorders. The company leverages proprietary technology platforms for drug discovery, clinical trial execution, and commercialization. Roivant advances investigational therapies through late-stage clinical trials while pursuing strategic licensing, partnerships, and asset acquisitions to expand its drug pipeline across multiple therapeutic domain areas globally.
Snapshot
Operations
Products and/or services of Roivant Sciences
- Autoimmune Therapeutics: Development and advancement of targeted biologic and small-molecule candidates for severe autoimmune and inflammatory conditions through specialized subsidiary entities, focusing on clinical evaluation and registrational trials.
- Dermatological Products: Commercialization and ongoing clinical trials for topical therapies and biological treatments targeting chronic dermatological conditions, including psoriasis and inflammatory skin disorders, distributed across primary healthcare and specialty pharmacy channels.
- Pulmonary Therapies: Clinical development of specialized investigational drug candidates aimed at severe respiratory and cardiovascular disorders, utilizing international clinical trial networks to evaluate therapeutic efficacy and patient safety parameters.
- Targeted Oncology Programs: Development of small molecule inhibitors and targeted protein degraders designed to address underlying molecular drivers in oncology, progressing proprietary biopharmaceutical assets through early and late phase clinical trial stages.
- Technology Platforms: Deployment of proprietary computational drug discovery systems, structural biology tools, and advanced data analytics platforms to identify viable therapeutic molecules and streamline clinical trial operational workflows.
- Vant Subsidiary Model: Strategic creation, capital allocation, and governance of focused biopharmaceutical operating subsidiaries, enabling dedicated management teams to advance specialized therapeutic programs, execute clinical trials, and pursue regulatory approvals.
Roivant Sciences executive team
- Mr. Matthew GlineCEO & Director
- Dr. Eric Venker M.D., Pharm.D.President & CEO of Immunovant
- Dr. Mayukh Sukhatme M.D.President, Chief Investment Officer & Director
- Mr. Richard PulikChief Financial Officer
- Ms. Jennifer HumesChief Accounting Officer
- Dr. Frank M. Torti M.B.A., M.D.President & Vant Chair
- Dr. Huafeng Xu Ph.D.Chief Technology Officer
- Mr. Ian RosenblumChief Information Officer
- Mr. Josh Chen J.D.General Counsel
- Ms. Kelly GraffHead of People